Afghanistan

Population 2018: 37 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>70 (45–100)</td>
<td>199 (122–270)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.32 (0.12–0.64)</td>
<td>0.87 (0.31–1.7)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>2.5 (1–4.7)</td>
<td>6.8 (2.9–13)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>11 (6.4–16)</td>
<td>29 (17–44)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.098 (0.036–0.19)</td>
<td>0.26 (0.1–0.52)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018
- New cases: 3% (1.4–5.3)
- Previously treated cases: 12% (11–14)

TB case notifications, 2018
- Total new and relapse: 48,420
  - % tested with rapid diagnostics at time of diagnosis: 24%
  - % with known HIV status: 53%
  - % pulmonary: 71%
  - % bacteriologically confirmed**: 64%
  - % children aged 0–14 years: 21%
  - % women: 46%
  - % men: 33%
- Total cases notified: 48,800

Universal health coverage and social protection
- TB treatment coverage (notified/estimated incidence), 2018: 69% (48–110)
- TB patients facing catastrophic total costs: 16% (8–26)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 11% (8–14)
- Patients with known HIV status who are HIV-positive: 7 <1%
  - on antiretroviral therapy: 3 43%

Drug-resistant TB care, 2018
- % of bacteriologically confirmed TB cases tested for rifampicin resistance**:
  - New cases: 49%
  - Previously treated cases: 95%

Laboratory-confirmed cases*
- MDR/RR-TB: 452, XDR-TB: 8
- MDR/RR-TB: 319, XDR-TB: 8

Patients started on treatment* **
- MDR/RR-TB cases tested for resistance to second-line drugs: 253

Treatment success rate and cohort size
- New and relapse cases registered in 2017: 91% 46,640
- Previously treated cases, excluding relapse, registered in 2017: 42% 766
- HIV-positive TB cases registered in 2017: 29% 7
- MDR/RR-TB cases started on second-line treatment in 2016: 62% 153
- XDR-TB cases started on second-line treatment in 2016: 62% 153

TB preventive treatment, 2018
- % of HIV-positive people (newly enrolled in care) on preventive treatment: 95% (88–100)
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 95% (88–100)

TB financing, 2019
- National TB budget (US$ millions): 17
  - Funding source: 3% domestic, 76% international, 21% unfunded

*Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-03-13 Data: www.who.int/tb/data